These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1308482)

  • 1. Evaluation of BACTEC 460 TB system for measurement of in vitro anti-Mycobacterium leprae activity of various antimicrobials.
    Tomioka H; Saito H; Sato K
    Nihon Rai Gakkai Zasshi; 1992 Nov; 61(3):157-64. PubMed ID: 1308482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy of benzoxazinorifamycin, KRM-1648, in combination with other antimicrobials against Mycobacterium leprae infection induced in nude mice.
    Saito H; Tomioka H; Sato K; Dekio S
    Int J Lepr Other Mycobact Dis; 1994 Mar; 62(1):43-7. PubMed ID: 8189088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug susceptibility testing of Mycobacterium leprae in the BACTEC 460 system.
    Franzblau SG
    Antimicrob Agents Chemother; 1989 Dec; 33(12):2115-7. PubMed ID: 2694952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro synergistic activity between ofloxacin and ansamycins against Mycobacterium leprae.
    Dhople AM; Ibanez MA; Gardner GD
    Arzneimittelforschung; 1993 Mar; 43(3):384-6. PubMed ID: 8387790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of aminoglycosides, lincosamides, and rifamycins against Mycobacterium leprae.
    Franzblau SG
    Antimicrob Agents Chemother; 1991 Jun; 35(6):1232-4. PubMed ID: 1929269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in-vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae.
    Dhople AM; Ibanez MA
    J Antimicrob Chemother; 1995 Apr; 35(4):463-71. PubMed ID: 7628981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Basic evaluation for new antimicrobial susceptibility testing of Mycobacterium leprae by bioluminescence assay (ATP method)].
    Yamazaki T; Gidoh M; Matsuoka M
    Nihon Hansenbyo Gakkai Zasshi; 2006 Sep; 75(3):227-37. PubMed ID: 17037377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of anti-bacterial activity of Rifapentine, Clarithromycin, Minocycline, Moxifloxacin, Ofloxacin and their combinations in Murine Model of Rifampicin Resistant Leprosy.
    Joseph P; Ponnaiya J; Das M; Chaitanya VS; Arumugam S; Ebenezer M
    Indian J Lepr; 2016; 88(3):147-58. PubMed ID: 30207440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
    Matsuoka M; Kashiwabara Y; Namisato M
    Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):452-5. PubMed ID: 11332288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in vitro activities of 20 fluoroquinolones against Mycobacterium leprae.
    Franzblau SG; White KE
    Antimicrob Agents Chemother; 1990 Feb; 34(2):229-31. PubMed ID: 2183714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activities of rifamycin analogues against Mycobacterium leprae.
    Dhople AM
    Indian J Lepr; 1997; 69(4):377-84. PubMed ID: 9474513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
    Dhople AM; Dimova V
    Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of sparfloxacin against Mycobacterium leprae measured by the proportional bactericidal test.
    McDermott-Lancaster RD; Banerjee DK
    Int J Lepr Other Mycobact Dis; 1993 Dec; 61(4):605-8. PubMed ID: 8151193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro activity of three new fluoroquinolones and synergy with ansamycins against Mycobacterium leprae.
    Dhople AM; Ibanez MA
    J Antimicrob Chemother; 1993 Sep; 32(3):445-51. PubMed ID: 8262866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo interactions of drugs used in multidrug therapy in leprosy.
    Dhople AM; Lamoureux LC; Gardner GD
    Indian J Lepr; 1991; 63(2):166-79. PubMed ID: 1664440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitazoxanide is active against Mycobacterium leprae.
    Bailey MA; Na H; Duthie MS; Gillis TP; Lahiri R; Parish T
    PLoS One; 2017; 12(8):e0184107. PubMed ID: 28850614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.
    Dhople AM; Namba K
    Int J Antimicrob Agents; 2003 Mar; 21(3):251-5. PubMed ID: 12636987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages.
    Rastogi N; Labrousse V; Goh KS
    Curr Microbiol; 1996 Sep; 33(3):167-75. PubMed ID: 8672093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid, radiometric in vitro assay for the evaluation of the anti-leprosy activity of clofazimine and its analogues.
    Mittal A; Seshadri PS; Conalty ML; O'Sullivan JF; Nath I
    Lepr Rev; 1985 Jun; 56(2):99-108. PubMed ID: 3894849
    [No Abstract]   [Full Text] [Related]  

  • 20. In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae.
    Dhople AM; Namba K
    J Infect Chemother; 2003 Mar; 9(1):12-5. PubMed ID: 12673400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.